Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01551329 · ClinicalTrials.gov registry record · Phase 1
Ketamine for Depression and Alcohol Dependence
A Phase 1 study, sponsored by Yale University.
- Completed
- Registry status
- Phase 1
- Development phase
- 5
- Enrollment target
NCT01551329: Completed Phase 1 study, sponsored by Yale University.
NCT01551329 is a Phase 1 study that has completed, run by Yale University. The registered enrollment target is 5 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01551329, a Phase 1 study, has completed, sponsored by Yale University.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 5 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the efficacy of ketamine in reducing depressive symptoms in subjects with a comorbid major depressive episode and alcohol dependence. The investigators hypothesize the following for the present study: A single dose of ketamine will induce a rapid, robust and sustained reduction in depressive symptoms in subjects with a comorbid major depressive episode and alcohol dependence relative to placebo as defined by change in Hamilton Depression Rating Scale total scores at 72 hours post infusion. A single dose of ketamine can be delivered safely, with minimal adverse events or complications, in subjects with a comorbid major depressive episode and alcohol dependence.
Primary Outcome
Measured using the Hamilton Depression Rating Scale
Interventions
- DRUG Ketalar (ketamine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 5 participants |
| Start Date | 2012-03 |
| Est. Completion | 2015-11 |
| Phase | Phase 1 |
What the finished NCT01551329 record still lists
NCT01551329 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 5 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (92% lower).
The record links to 0 conditions, and to 1 intervention - of which Ketalar (ketamine) is the first listed.
NCT01551329 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01551329 about?
NCT01551329 is a clinical study titled "Ketamine for Depression and Alcohol Dependence". The purpose of this study is to evaluate the efficacy of ketamine in reducing depressive symptoms in subjects with a comorbid major depressive episode and alcohol dependence. The investigators hypothesize the following for the present study: A single dose of ketamine will induce a rapid, robust and...
What is the current status of trial NCT01551329?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 5 participants. The study started on 2012-03. Estimated completion is 2015-11.
What interventions are being tested in trial NCT01551329?
The interventions under investigation include: Ketalar (ketamine) (DRUG).
Who is sponsoring clinical trial NCT01551329?
This trial is sponsored by Yale University, which has 1,492 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01551329's enrollment target sits among peer trials
5 1989th of 2000 higher than 6 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia